Overview

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body weight, and assessed the safety and tolerability of a range of doses of Met DR when administered in subjects with type 2 diabetes mellitus (T2DM).
Phase:
Phase 2
Details
Lead Sponsor:
Elcelyx Therapeutics, Inc.
Treatments:
Metformin